Clinre Inc

1. Eli Lilly and Company $84,166 2 payments
2. Abbott Laboratories $57,275 24 payments
3. Terumo Medical Corporation $52,683 30 payments
4. Pfizer Inc. $51,766 7 payments
5. MedAlliance LLC $43,673 5 payments
6. AngioDynamics, Inc. $20,000 1 payment
7. Sanofi US Services Inc. $18,501 8 payments
8. Bard Peripheral Vascular, Inc. $555 4 payments

1. A Phase 3, Randomized, Multicenter, Double-Blind Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly Compared With Placebo in Adult Participants With Type 2 Diabetes, Moderate Or Severe Renal Impairment With Inadequate Glycemic Control on Basal Insulin With Or Without Metformin And/Or Sglt2 Inhibitor $84,166 2 payments
2. Osprey Iliac: Occlusive/Stenotic Peripheral Artery Revascularization Study for Common And/Or External Iliac Artery Using the Misago RX Self-Expanding Peripheral Stent $52,683 30 payments
3. An Interventional Openlabel Randomized Multicenter Phase 3 Study of Pf07220060 Plus Letrozole Compared to Cdk46 Inhibitor Plus Letrozole in Participants Over 18 Years of Age With Hormone Receptor Hrpositive Her2negative Advancedmetastatic Breast Cancer Who Have Not Received Any Prior Systemic Anticancer Treatment for Advancedmetastatic Disease Fourlight3 $51,766 7 payments
4. JET Enhanced Thrombectomy intervention Registry $33,346 9 payments
5. A Prospective Randomized Multicenter Single Blinded Study to Assess the Safety and Efficacy of the SELUTION SLR 018 Drug Eluting Balloon in the Treatment of Subjects With Femoropopliteal Artery Lesions $31,173 3 payments
6. Auryon Laser Patient Series $20,000 1 payment
7. A Real-World Observational Study Characterizing Patients With Type 1 Diabetes Treated with Teplizumab (TEPLI-REAL) $18,501 8 payments
8. NCT04370691--JETi Lower Extremity Arterial Thrombosis $12,809 9 payments
9. A Prospective Randomized Multicenter Single Blinded Study to Assess the Safety and Effectiveness of the SELUTION SLR 014 Drug Eluting Balloon in the Treatment of Below-the-Knee (BTK) Atherosclerotic Disease in Patients With Chronic Limb Threatening Ischemia (CLTI) $12,500 2 payments
10. NCT06656364--Esprit BTK Post-Approval Study $10,070 4 payments

1. Other $20,000 1 payment

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.